Loading
Valneva SE operates as a specialized biopharmaceutical company, concentrating its efforts on developing and bringing to market preventative vaccines for infectious diseases where current medical options are insufficient. Its portfolio of commercial travel vaccines includes IXIARO, an inactivated vaccine derived from Vero cell culture, which provides active immunity against Japanese encephalitis. Another offering is DUKORAL, an oral vaccine designed to guard against diarrhea induced by Vibrio cholerae or enterotoxigenic Escherichia coli (ETEC) bacteria. The company's development pipeline features VLA2001, a candidate vaccine targeting SARS-CoV-2. Additionally, Valneva is progressing with VLA15, a Lyme disease vaccine candidate that has successfully concluded Phase II clinical trials and is being co-developed and commercialized with Pfizer, Inc. They are also advancing VLA1553, a chikungunya virus vaccine candidate currently undergoing Phase III clinical evaluation, in partnership with Instituto Butantan for its development, production, and marketing as a single-shot vaccine. Valneva's products are sold across a wide geographical area, including the United States, Canada, Germany, Austria, the Nordic countries, the United Kingdom, various other European nations, and internationally. Founded in 1998, the company maintains its headquarters in Saint-Herblain, France.
Previous close
$5.69
−$0.18 · -3.07%
After-hours
$5.74
+$0.05 · +0.88%
Oct 8, 4:10 PM ET
Regular session · ET · Market data may be delayed.
Valneva SE operates as a specialized biopharmaceutical company, concentrating its efforts on developing and bringing to market preventative vaccines for infectious diseases where current medical options are insufficient. Its portfolio of commercial travel vaccines includes IXIARO, an inactivated vaccine derived from Vero cell culture, which provides active immunity against Japanese encephalitis. Another offering is DUKORAL, an oral vaccine designed to guard against diarrhea induced by Vibrio cholerae or enterotoxigenic Escherichia coli (ETEC) bacteria. The company's development pipeline features VLA2001, a candidate vaccine targeting SARS-CoV-2. Additionally, Valneva is progressing with VLA15, a Lyme disease vaccine candidate that has successfully concluded Phase II clinical trials and is being co-developed and commercialized with Pfizer, Inc. They are also advancing VLA1553, a chikungunya virus vaccine candidate currently undergoing Phase III clinical evaluation, in partnership with Instituto Butantan for its development, production, and marketing as a single-shot vaccine. Valneva's products are sold across a wide geographical area, including the United States, Canada, Germany, Austria, the Nordic countries, the United Kingdom, various other European nations, and internationally. Founded in 1998, the company maintains its headquarters in Saint-Herblain, France.
Day range
Current $5.69
52-week range
Current $5.69
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
49
Fair Value
Sentiment
53
Mixed
Risk
64
High Risk
Momentum
21
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Valneva SE operates as a specialized biopharmaceutical company, concentrating its efforts on developing and bringing to market preventative vaccines for infectious diseases where current medical options are insufficient. Its portfolio of commercial travel vaccines includes IXIARO, an inactivated vaccine derived from Vero cell culture, which provides active immunity against Japanese encephalitis. Another offering is DUKORAL, an oral vaccine designed to guard against diarrhea induced by Vibrio cholerae or enterotoxigenic Escherichia coli (ETEC) bacteria. The company's development pipeline features VLA2001, a candidate vaccine targeting SARS-CoV-2. Additionally, Valneva is progressing with VLA15, a Lyme disease vaccine candidate that has successfully concluded Phase II clinical trials and is being co-developed and commercialized with Pfizer, Inc. They are also advancing VLA1553, a chikungunya virus vaccine candidate currently undergoing Phase III clinical evaluation, in partnership with Instituto Butantan for its development, production, and marketing as a single-shot vaccine. Valneva's products are sold across a wide geographical area, including the United States, Canada, Germany, Austria, the Nordic countries, the United Kingdom, various other European nations, and internationally. Founded in 1998, the company maintains its headquarters in Saint-Herblain, France.
Day range
Current $5.69
52-week range
Current $5.69
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (EUR) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 174.66M EUR | 169.58M EUR | 153.71M EUR | 361.3M EUR | 348.09M EUR |
| Cost of goods sold | 107.14M EUR | 98.54M EUR | 100.88M EUR | 324.44M EUR | 187.92M EUR |
| Gross profit | 67.52M EUR | 71.04M EUR | 52.84M EUR | 36.86M EUR | 160.17M EUR |
| Research and development | 85.3M EUR | 74.14M EUR | 59.89M EUR | 104.92M EUR | 173.28M EUR |
| Selling, general, and administrative | 74.68M EUR | 95.11M EUR | 96.55M EUR | 57.58M EUR | 71.25M EUR |
| Operating expenses | 149.15M EUR | 57.71M EUR | 134.92M EUR | 150.31M EUR | 221.56M EUR |
| Interest income | 1.8M EUR | 2.36M EUR | 1.21M EUR | 260K EUR | 249K EUR |
| Interest expense | 41.9M EUR | 23.98M EUR | 23.33M EUR | 19.05M EUR | 16.96M EUR |
| Depreciation and amortization | 21.75M EUR | 19.59M EUR | 17.58M EUR | 21.04M EUR | 14.28M EUR |
| Operating income | −81.63M EUR | 13.33M EUR | −82.09M EUR | −113.44M EUR | −61.39M EUR |
| Net income | −115.19M EUR | −12.25M EUR | −101.43M EUR | −143.28M EUR | −73.43M EUR |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
